单次静脉注射尼可地尔对ST段抬高的急性心肌梗死再灌注前的影响

• 作 者: Hideki Ishii Satoshi Ichimiya Masaaki Kanashiro Tetsuya Amano Kenji Imai Toyoaki Murohara Tatsuaki Matsubara 田玉敬
• 机 构: 北京四环科宝制药有限公司,
• 出 处: 首都食品与医药
• 发表日期: 2015年14期
• 关键词: 单次静脉注射 尼可地尔 段抬高 急性心肌梗塞 梗死再灌注 再灌注治疗 闭塞冠状动脉 血栓溶解 经皮冠状 功能障碍 梗塞面积 住院率 药理学 死亡率 心脏 病人

(接6月下)主要临床结果见附表3。终点定义为心血管死亡或者因CHF入院,12(6.5%)例病人接受尼可地尔治疗,30(16.4%)人给予安慰剂(危害比,0.39;95%CI,0.20~0.76;P=0.0058)(见附图)。尼可地尔组有6(3.2%)例病人,安慰剂组有20(10.9%)例病人因CHF恶化而意外入院治疗(危害比,0.29;95%CI,0.11~0.71;P=0.0072)。心血管死亡

(Continued next June) the main clinical results in Schedule 3. Endpoints were defined as cardiovascular death or admission to hospital for CHF, 12 (6.5%) received nicorandil and 30 (16.4%) received placebo (hazard ratio 0.39; 95% CI 0.20-0.76; P = 0.0058) (see attached figure). Six (3.2%) patients in the nicorandil group and 20 (10.9%) patients in the placebo group were admitted admissions for worsening CHF (hazard ratio, 0.29; 95% CI, 0.11 to 0.71; P = 0.0072) . Cardiovascular death